Middle East Pharmaceutical Industries Co. (4016.SR)
SAR 119.8
(-0.33%)
SAR 119.8
(-0.33%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 128.79 Million SAR | 19.99% |
| 2022 | 107.33 Million SAR | 15.78% |
| 2021 | 92.71 Million SAR | 2.2% |
| 2020 | 90.71 Million SAR | 9.84% |
| 2019 | 82.59 Million SAR | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 39.82 Million SAR | 15.39% |
| 2024 Q1 | 34.13 Million SAR | 2.54% |
| 2023 Q4 | 33.28 Million SAR | 0.0% |
| 2023 Q3 | 33.28 Million SAR | 11.47% |
| 2023 FY | 120.97 Million SAR | 12.71% |
| 2023 Q2 | 29.85 Million SAR | -4.09% |
| 2023 Q1 | 31.13 Million SAR | 5.96% |
| 2022 Q1 | 27.46 Million SAR | 0.0% |
| 2022 FY | 107.33 Million SAR | 15.78% |
| 2022 Q4 | 29.38 Million SAR | 0.0% |
| 2022 Q2 | 23.56 Million SAR | -14.21% |
| 2022 Q3 | 29.38 Million SAR | 24.71% |
| 2021 FY | 92.71 Million SAR | 2.2% |
| 2020 FY | 90.71 Million SAR | 9.84% |
| 2019 FY | 82.59 Million SAR | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Al-Dawaa Medical Services Company | 1.59 Billion SAR | 91.94% |
| Nahdi Medical Company | 2.47 Billion SAR | 94.796% |
| Al-Razi Medical Co. | 12.26 Million SAR | -950.409% |
| Almujtama Alraida Medical Co. | 115.25 Million SAR | -11.745% |